Factors influencing drug uptake during mass drug administration for control of lymphatic filariasis in rural and urban Tanzania

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Kisoka, William J ^a,c   Simonsen, Paul E ^b   Malecela, Mwelecele N ^a   Tersbøl, Britt P ^b   Mushi, Declare L ^c   Meyrowitsch, Dan W ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; IVERMECTIN;

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; CHILD; CHRISTIAN; COMMUNITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; GROUPS BY AGE; HOME; HOUSEHOLD; HUMAN; INFECTION CONTROL; LYMPHATIC FILARIASIS; MALE; MASS DRUG ADMINISTRATION; MUSLIM; QUESTIONNAIRE; RURAL AREA; SELF REPORT; SEX RATIO; TANZANIA; TREATMENT CONTRAINDICATION; URBAN AREA; ELEPHANTIASIS, FILARIAL; PATIENT ATTITUDE; PRESCHOOL CHILD; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; URBAN POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; ALBENDAZOLE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ELEPHANTIASIS, FILARIAL; FEMALE; HUMANS; IVERMECTIN; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; RURAL POPULATION; TANZANIA; URBAN POPULATION; YOUNG ADULT;

EID: 84907741814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109316     Document Type: Article

References (34)

1. Ahorlu CK, Dunyo SK, Asamoah G, Simonsen PE (2001) Consequences of hydrocoele and the benefits of hydrocoelectomy: a qualitative study in lymphatic filariasis endemic communities on the coast of Ghana. Acta Trop 80: 215-221.
2. WHO (2013) Lymphatic filariasis: Managing morbidity and preventing disability. Geneva: World Health Organization.
3. nd edition. London: Saunders Elsevier Limited. Pp 737-765.
4. Ottesen EA (2006) Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 61: 395-441.
5. Hotez PJ, Kamath A (2009) Neglected tropical diseases in Sub-Saharan Africa: review of their prevalence, distribution and disease burden. PLoS Negl Trop Dis 3: e412.
6. Simonsen PE, Mwakitalu ME (2013) Urban lymphatic filariasis. Parasitol Res 112: 35-44.
7. WHO (2010) Global Programme to Eliminate Lymphatic Filariasis. Progress report 2000-2009 and strategic plan 2010-2020. Geneva: World Health Organization.
8. WHO (2006) Preventive chemotherapy in human helminthiasis. Geneva: World Health Organization.
9. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, et al. (2004) Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 4: 223-234.
10. WHO (2011) Monitoring and epidemiological assessment of mass drug administration in the Global Programme to Eliminate Lymphatic Filariasis. A manual for national elimination programmes. Geneva: World Health Organization.
11. Krentel A, Fischer PU, Weil GJ (2013) A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis 7: e2447.
12. Gunawardena S, Ismail M, Bradley M, Karunaweera N (2007) Factors influencing drug compliance in the mass drug administration programme against filariasis in the Western Province of Sri Lanka. Trans R Soc Trop Med Hyg 101: 445-453.
13. Amarillo ML, Belizario VY Jr, Sadiang-Abay JT, Sison SA, Dayag AM (2008) Factors associated with the acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasit Vectors 1: 14.
14. Babu BV, Mishra S (2008) Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Trans R Soc Trop Med Hyg 102: 1207-1213.
15. King JD, Zielinski-Gutierrez E, Pa'au M, Lammie P (2011) Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Trop 120: 548-554.
16. Nujum ZT (2011) Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India. Int Health 3: 22-26.
17. Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Njenga SM (2012a) The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS One 7: e48395.
18. Offei M, Anto F (2014) Compliance to mass drug administration programme for lymphatic filariasis elimination by community members and volunteers in the Ahanta West District of Ghana. J Bacteriol Parasitol 5: 1.
19. Minjas JN, Kihamia CN (1991) Bancroftian filariasis. In: Mwaluko GMP, Kilama WL, Mandara MP, Murru M, Mcpherson CNL, editors. Health and Disease in Tanzania. London: Harper Collins Academic. pp 159-176.
20. McMahon JE, Magayuka SA, Kolstrup N, Mosha FW, Bushrod FM, et al. (1981) Studies on the transmission and prevalence of bancroftian filariasis in four coastal villages of Tanzania. Ann Trop Med Parasitol 75: 415-431.
21. Meyrowitsch DW, Simonsen PE, Makunde WH (1995) Bancroftian filariasis: analysis of infection and disease in five endemic communities of north-eastern Tanzania. Ann Trop Med Parasitol 89: 653-663.
22. Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P (1995) Bancrotian filariasis: The pattern of microfilaraemia and clinical manifestations in three endemic communities of Northeastern Tanzania. Acta Trop 60: 179-187.
23. Simonsen PE, Meyrowitsch DW, Jaoko WG, Malecela MN, Mukoko D, et al. (2002) Bancroftian filariasis infection, disease, and specific antibody response patterns in a high and a low endemicity community in East Africa. Am J Trop Med Hyg 66: 550-559.
24. Rwegoshora RT, Pedersen EM, Mukoko DA, Meyrowitsch DW, Masese N, et al. (2005) Bancroftian filariasis: patterns of vector abundance and transmission in two East African communities with different levels of endemicity. Ann Trop Med Parasitol 99: 253-265.
25. Malecela MN, Lazarus WM, Mwingira U, Mwakitalu E, Makene C, Mackenzie CD (2009) Eliminating LF: a Progress Report from Tanzania. J Lymph 4: 10-12.
26. Allen T, Parker M (2011) The 'Other Diseases' of the Millennium Development Goals: rhetoric and reality of free drug distribution to cure the poor's parasites. Third World Quarterly 32: 91-117.
27. Parker M, Allen T (2013) Will mass drug administration eliminate lymphatic filariasis? Evidence from Northern coastal Tanzania. J Biosocial Sci 45: 517-545.
28. Simonsen PE, Derua YA, Kisinza WN, Magesa SM, Malecela MN, et al. (2013) Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission. BMC Infect Dis 13: 335.
29. Cantey PT, Rao G, Rout J, Fox LM (2010) Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop Med Int Health 15: 224-231
30. NBS (2013) Population and housing census 2012. Volume I. Population distribution by administrative units. Tanzania: National Bureau of Statistics.
31. Babu BV, Kar SK (2004) Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9: 702-709.
32. Mathieu E, Direny AN, de Rochers MB, Streit TG, Addiss DG, Lammie PJ (2006) Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health 11: 862-868.
33. El-Setouhy M, Elaziz KMA, Helmy H, Farid HA, Kamal HA, et al. (2007) The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg 77: 1069-1073.
34. WHO (2006) Quality of care. A process for making strategic choices in health systems. Geneva: World Health Organization.